Opinion|Videos|April 29, 2024
Comparing BTK Inhibitors for Optimal CLL Treatment
Nitin Jain, MD, discusses the increasing use of various Bruton's tyrosine kinase inhibitors as front-line treatment options for patients with chronic lymphocytic leukemia.
Advertisement
Advertisement
Related to this article
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
4
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
5